Lecanemab (Mouse IGG2a)  (Synonyms: Mab158)

Lecanemab (Mouse IGG2a) (Mab158) is a monoclonal antibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) almost abolishes Aβ accumulation in astrocytes and rescues neurons from Aβ-induced cell death. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease^[1][2][3].

Mouse IgG2a kappa

Mouse IgG2a kappa, Isotype Control

Human

Amyloid Beta/Aβ

Lecanemab (Mouse IGG2a) (13 nM, 24 h) almost abolishes Aβ accumulation in astrocytes and rescues neurons from Aβ-induced cell death in co-cultures of astrocytes, neurons, and oligodendrocytes derived from embryonic mouse cortex^[1].
Lecanemab (Mouse IGG2a) (13 nM, 24 h) still exerts Aβ-lowering effect in co-cultures pre-treated with proteasomal inhibitor MG-132 (HY-13259) or lysosomal inhibitor Bafilomycin (HY-100558)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Lecanemab (Mouse IGG2a) (as [¹²⁴I]RmAb158-scFv8D3) generates significant retention signals in cerebral cortex, hippocampus and thalamus of tg-ArcSwe and tg-Swe mice, with signal intensity comparable to [¹²⁴I]RmAb3D6-scFv8D3^[2].
Lecanemab (Mouse IGG2a) displays very faint staining in tg-UppSwe mouse brain sections, while showing strong staining overlapping with Aβ₄₀+Aβ₄₂ positive areas in tg-ArcSwe and tg-Swe mouse brain sections^[2].
Lecanemab (Mouse IGG2a) (10 mg/kg, i.p., once weekly, for 4/13 weeks) exhibits significant anti-Alzheimer's disease (AD) pathological effects in the tg-ArcSwe transgenic mouse model harboring the APP Arctic mutation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

351  [NCBI]

P05067

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

147.71 kDa

Liquid

Colorless to light yellow

[Lecanemab (Mouse IGG2a)]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Flow cytometric analysis of 1X10⁶ HUVEC cells with Lecanemab (HY-P990110, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti- Mouse IgG H&L (HY-P8005) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Mouse IgG2a kappa (HY-P99978, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Söllvander S, et al. The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death. J Neuroinflammation. 2018 Mar 28;15(1):98.  [Content Brief]

  [2]. Rizoska B, et al. Disease modifying effects of the amyloid-beta protofibril-selective antibody mAb158 in aged Tg2576 transgenic mice. Mol Cell Neurosci. 2024 Sep;130:103950.  [Content Brief]

  [3]. Tucker S, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575-88.  [Content Brief]